- Home
- ALAR vs ZNTL Comparison
ALAR vs ZNTL Comparison
Compare ALAR & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAR
- ZNTL
- Stock Information
- Founded
- ALAR 2013
- ZNTL 2014
- Country
- ALAR Israel
- ZNTL United States
- Employees
- ALAR N/A
- ZNTL N/A
- Industry
- ALAR Computer Software: Prepackaged Software
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- ALAR Technology
- ZNTL Health Care
- Exchange
- ALAR Nasdaq
- ZNTL Nasdaq
- Market Cap
- ALAR 45.3M
- ZNTL 105.8M
- IPO Year
- ALAR 2018
- ZNTL 2020
- Fundamental
- Price
- ALAR $12.30
- ZNTL $1.33
- Analyst Decision
- ALAR Strong Buy
- ZNTL Buy
- Analyst Count
- ALAR 1
- ZNTL 7
- Target Price
- ALAR $15.00
- ZNTL $8.60
- AVG Volume (30 Days)
- ALAR 162.4K
- ZNTL 1.4M
- Earning Date
- ALAR 08-25-2025
- ZNTL 08-08-2025
- Dividend Yield
- ALAR N/A
- ZNTL N/A
- EPS Growth
- ALAR N/A
- ZNTL N/A
- EPS
- ALAR 0.07
- ZNTL N/A
- Revenue
- ALAR $30,581,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- ALAR N/A
- ZNTL N/A
- Revenue Next Year
- ALAR $12.28
- ZNTL N/A
- P/E Ratio
- ALAR $19.30
- ZNTL N/A
- Revenue Growth
- ALAR 4.67
- ZNTL N/A
- 52 Week Low
- ALAR $5.45
- ZNTL $1.01
- 52 Week High
- ALAR $37.19
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- ALAR 55.68
- ZNTL 50.91
- Support Level
- ALAR $13.20
- ZNTL $1.15
- Resistance Level
- ALAR $14.63
- ZNTL $1.38
- Average True Range (ATR)
- ALAR 1.01
- ZNTL 0.10
- MACD
- ALAR -0.13
- ZNTL 0.01
- Stochastic Oscillator
- ALAR 48.24
- ZNTL 75.00
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.